CTI BIOPHARMA
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2014-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.ctibiopharma.com/
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 450
- Registration Number
- NCT00551733
- Locations
- 🇺🇸
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
🇺🇸Broward Oncology Associates, Fort Lauderdale, Florida, United States
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00551239
- Locations
- 🇺🇸
Cell Therapeutics, Incorporated, Seattle, Washington, United States
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 48
- Registration Number
- NCT00291785
- Locations
- 🇮🇹
Policlinico Universitario "A.Gemelli", Rome, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, Italy
CT-2106 for the Second Line Treatment of Ovarian Cancer
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 40
- Registration Number
- NCT00291837
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
- Conditions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 600
- Registration Number
- NCT00269828
- Locations
- 🇦🇷
Hospital General de Agudos "Dr Teodoro Alvarez", Buenos Aires, Argentina
🇦🇷LUCEN, Cuidad Autonoma de Buenos Aires, Argentina
🇦🇷ISIS Clinica Especializada, Urquiza, Argentina
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 124
- Registration Number
- NCT00268853
- Locations
- 🇺🇸
Western Kentucky Hematology/Oncology Group, Paducah, Kentucky, United States
🇺🇸Hubert H Humphrey Cancer Center, Robbinsdale, Minnesota, United States
🇺🇸Texas Hematology Oncology Center, Dallas, Texas, United States
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
- Conditions
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 12
- Registration Number
- NCT00106600
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
- Conditions
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 80
- Registration Number
- NCT00004026
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸Stanley Scott Cancer Center, New Orleans, Louisiana, United States
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 140
- Registration Number
- NCT00088530
- Locations
- 🇪🇨
Hospital Solca Quito, Quito, Ecuador
🇫🇷Institute Bergonie, Bordeaux, France
🇩🇪Charite, Campus Benjamin Franklin, Berlin, Germany
Arsenic Trioxide in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00017433
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Scripps Clinic, La Jolla, California, United States